Delcath Systems Announces 10-Year Retrospective Study on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

Delcath Systems announces the publication of a retrospective study in the journal Cancers, reporting outcomes from 38 patients with liver-dominant metastatic uveal melanoma who underwent percutaneous hepatic perfusion with CHEMOSAT Hepatic Delivery System for Melphalan. The study demonstrates a median overall survival of 29.1 months and improved outcomes with additional treatment cycles. The results reinforce the potential survival benefits of PHP treatment, highlighting the safety and efficacy of CHEMOSAT in a real-world setting.